Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET
– Event to review initial clinical data from APEX, a Phase 2 trial with bezuclastinib in Advanced Systemic Mastocytosis presented at European Hematology Association (EHA) Congress
CAMBRIDGE, Mass. and BOULDER, Colo., June 06, 2022 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it will host an investor webcast on Friday, June 10, 2022 at 8:00am ET (2:00pm CEST) to discuss initial clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the European Hematology Association (EHA) Congress.
The event will be led by Andrew Robbins, Cogent’s President and CEO, and will include a presentation by Daniel J. DeAngelo, M.D., Ph.D., Chief of the Division of Leukemia at the Dana-Farber Cancer Institute. The speakers and additional members of Cogent leadership will be available during the Question and Answer session.
Dial-in Number
U.S./Canada Dial-in Number: 844-686-3753
International Dial-in Number: 704-753-0395
Conference ID: 2951969
Replay Dial-in Number: 855-342-0870
Replay International Dial-in Number: 442-268-1018
Conference ID: 2951969
The webcast will be accessible through the Investors and Media section of Cogent’s website at www.cogentbio.com. Following the live webcast, an archived replay will also be available.
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting FGFR2 and ErbB2. Cogent Biosciences is based in Cambridge, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.
Contact:
Christi Waarich
Senior Director, Investor Relations
617-830-1653
christi.waarich@cogentbio.com
